EMA Authorised: Velcade (bortezomib) — Janssen-Cilag International NV

View source ↗

Summary

The EMA authorised Velcade (bortezomib) from Janssen-Cilag International NV for use in multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Janssen-Cilag International NV. Decision date: 16/10/2024